Decision on optimal combinatorial Therapies in IMIDS using Systems Approaches

Project Overview

DoCTIS is an EU-funded translational project aimed at addressing the urgent need to discover effective therapeutic strategies for immune-mediated inflammatory diseases.


Biomedical research partners from five different European countries as well as from the United States of America are collaborating toward this.

Work Packages

The DoCTIS project is structured in nine different work packages, involving animal model, patient, systems biology and clinical evaluation stages.


DoCTIS is the acronym for the EU-funded project entitled “Decision on Combinatorial Therapies in Immune-Mediated diseases using Systems approaches”. DoCTIS is a multicentric project involving diverse basic, applied and clinical research centres from Spain, Sweden, Italy, Germany, UK and USA aimed at improving treatment efficacy in six Immune-Mediated Inflammatory Diseases (IMIDs), encompassing: Crohn’s disease, ulcerative colitis, rheumatoid arthritis, systemic lupus erythematosus, psoriasis and psoriatic arthritis. Through the generation of high volumes of data using of modern high-throughput technologies on samples from well-characterized IMID patients, and the use of advanced systems biology analytical approaches, we aim to identify therapeutic combinations that are much more efficacious and safer than current single-drug approaches.


Follow the most recent activity generated from the DoCTIS project.


See DoCTIS in the media and published work derived from the project.


Calendar of future and past events associated to the DoCTIS project.


If you are a patient suffering from an IMID, click here to know more on how the research at the DoCTIS project is working to help you.

Researchers report promising results in search for #combinationtherapy strategy that may in work in #acutemyeloidleukemia (AML). #MDM2 #BET #oncology #targetedtherapy #TP53 #moleculardiagnostics

CIRCULOGENE: One Tube, One Week, Complete Results

Researchers find that combination therapies may be the key in fighting tumors that become resistant to a specific drug.

#stemcell #cancer #combinationtherapy

📢 I’m urgently for looking 1 high-level bioinformatician with strong background in math/computer science that is interested to apply to a great PhD program with me in the application of single-cell and spatial genomics ( Deadline: 25/01/21 . Pls RTW!

#doctis partner @ErnestChoy1 #cardiffuniversity reviews past, present and future of therapies targeting #interleukin6 receptor

#doctis partner Prof Britta Siegmund #chariteberlin reviews markers for successful anti-TNF therapy in IBDs

Load More…